These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29851929)

  • 1. How should BRAF V600E-mutated colorectal cancer be treated?
    Kopetz S
    Clin Adv Hematol Oncol; 2018 May; 16(5):333-335. PubMed ID: 29851929
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
    Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
    J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
    Amrane K; le Pennec R; Schick U; Metges JP; Abgral R
    Clin Nucl Med; 2020 Sep; 45(9):707-708. PubMed ID: 32657876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer.
    Owaki S; Mori Y; Nakai S; Maeda H; Imazu M; Tomita Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Hirano A; Kimura Y; Tsuchida K; Kataoka H
    Intern Med; 2024 Jul; 63(14):1995-1999. PubMed ID: 37981300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat chemorefractory metastatic colorectal cancer.
    Chu E
    Clin Adv Hematol Oncol; 2018 May; 16(5):340-345. PubMed ID: 29851930
    [No Abstract]   [Full Text] [Related]  

  • 11. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy in colorectal cancer.
    Berlin J
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
    Berlin J
    N Engl J Med; 2013 Sep; 369(11):1059-60. PubMed ID: 24024844
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Normanno N; Tejpar S; Ciardiello F
    J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
    [No Abstract]   [Full Text] [Related]  

  • 17. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
    Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
    Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
    González Astorga B; Salvà Ballabrera F; Aranda Aguilar E; Élez Fernández E; García-Alfonso P; González Flores E; Vera García R; Fernández Montes A; López Muñoz AM; Salud Salvia A
    Clin Transl Oncol; 2021 Aug; 23(8):1520-1528. PubMed ID: 33630242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.